Director
Merck & Co., Inc.
Rahway, New Jersey
Dr. Sachin Lohani, PhD is currently serving as Director Analytical Research & Development, Merck Research Laboratories. His group supports analytical characterization of drug substance and drug product from early development to commercialization. Sachin received his PhD in Pharmaceutics from University of Minnesota. He started his professional career in 2006 at Merck and held positions with increasing responsibilities within various organizations in MRL. In 2014, he joined FDA’s Office of Pharmaceutical Science as a CMC reviewer and then served as a Policy Analyst/Acting Branch Chief in the Office of Policy in Pharmaceutical quality. After his tenure at FDA, he joined Jansen Pharmaceuticals (Johnson & Johnson), where he established the group responsible for conducting developability assessment of discovery compounds at the Spring House PA site. Prior to his current role, Sachin was serving as director of pharmaceutical development at Celgene, where he was responsible for leading cross-functional pharmaceutical development teams responsible for meeting CMC milestones from Phase 1 through registration.
Disclosure information not submitted.
Nitrosamine Analysis and Control
Tuesday, July 23, 2024
8:00 AM – 10:05 AM CST
Nitrosamine Analysis and Control - Continued
Tuesday, July 23, 2024
10:25 AM – 11:30 AM CST
Rapid Fire Presentations: Pharmaceutical Analysis
Wednesday, July 24, 2024
3:30 PM – 4:15 PM CST
Challenges in Analytical Method Validations and Transfers: Bio and Pharm Joint Session
Thursday, July 25, 2024
8:00 AM – 10:40 AM CST
Joint Session: Panel Discussion
Thursday, July 25, 2024
10:05 AM – 10:35 AM CST